-
Mashup Score: 3Biogen says it will cut costs by $700 million, slash 1,000 jobs - 9 month(s) ago
Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.
Source: www.statnews.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Biogen’s boardroom scandal saddles CEO with first crisis - 10 month(s) ago
This was supposed to be the new Biogen. Then came another boardroom controversy.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1FDA advisory panel recommends conditional approval of Biogen's drug for rare form of ALS - 1 year(s) ago
The FDA panel voted 9-0 for conditional approval of Biogen’s drug for a rare form of ALS, but split over whether data supported full approval.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of the Alzheimer’s treatment Aduhelm, has left the company, STAT has learned.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0New Biogen CEO: New drug launches, more cost cuts, but no 'radical left turns' needed - 1 year(s) ago
SAN FRANCISCO — In some of his first extended comments since taking over as Biogen’s CEO, Chris Viehbacher described the commercial launches this year of
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer's treatments - 1 year(s) ago
Crucial questions remain for the Food and Drug Administration, Biogen, and the future of treating Alzheimer’s disease.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 5FDA, Biogen, and an Alzheimer's drug approval: 8 key takeaways from congressional investigation - 1 year(s) ago
Here are eight key takeaways from the congressional investigation of the FDA’s approval of the Biogen Alzheimer’s drug Aduhelm.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds - 1 year(s) ago
The downfall of Aduhelm is largely the story of Biogen choosing to maximize its potential profits at the expense of patients and taxpayers, investigators found.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0FDA, Biogen, and an Alzheimer's drug approval: 8 key takeaways from congressional investigation - 1 year(s) ago
Here are eight key takeaways from the congressional investigation of the FDA’s approval of the Biogen Alzheimer’s drug Aduhelm.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 7Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds - 1 year(s) ago
The downfall of Aduhelm is largely the story of Biogen choosing to maximize its potential profits at the expense of patients and taxpayers, investigators found.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
#Biogen plans to save $700 million in operating costs and cut 1,000 jobs by 2025. https://t.co/hT47WWLo3T